Article
Authorship
MERCOGLIANO, MARIA FLORENCIA
;
Bruni, Sofia
;
Mauro, Florencia Luciana
;
Elizalde, Patricia Virginia
;
SCHILLACI, ROXANA
Date
2021
Publishing House and Editing Place
MDPI AG
Magazine
Cancers,
vol. 13
(pp. 1-33)
- ISSN 2072-6694
MDPI AG
MDPI AG
ISSN
2072-6694
Summary
Information provided by the agent in
SIGEVA
Tumor necrosis factor alpha (TNF?) is a pleiotropic cytokine known to have contradictory roles in oncoimmunology. Indeed, TNF? has a central role in the onset of the immune response, inducing both activation and the effector function of macrophages, dendritic cells, natural killer (NK) cells, and B and T lymphocytes. Within the tumor microenvironment, however, TNF? is one of the main mediators of cancer-related inflammation. It is involved in the recruitment and differentiation of immune suppre...
Tumor necrosis factor alpha (TNF?) is a pleiotropic cytokine known to have contradictory roles in oncoimmunology. Indeed, TNF? has a central role in the onset of the immune response, inducing both activation and the effector function of macrophages, dendritic cells, natural killer (NK) cells, and B and T lymphocytes. Within the tumor microenvironment, however, TNF? is one of the main mediators of cancer-related inflammation. It is involved in the recruitment and differentiation of immune suppressor cells, leading to evasion of tumor immune surveillance. These characteristics turn TNF? into an attractive target to overcome therapy resistance and tackle cancer. This review focuses on the diverse molecular mechanisms that place TNF? as a source of resistance to immunotherapy such as monoclonal antibodies against cancer cells or immune checkpoints and adoptive cell therapy. We also expose the benefits of TNF? blocking strategies in combination with immunotherapy to improve the antitumor effect and prevent or treat adverse immune-related effects.
Show more
Show less
Key Words
IMMUNOTHERAPYIMMUNE CHECKPOINT INHIBITORCANCERTNF?ADOPTIVE CELL THERAPYMONOCLONAL ANTIBODY
Download or request the full text